XXX Congreso Nacional 09 al 07 de Noviembre de
2014 Hotel Hesperia
World Trade Center Valencia - Edo. CaraboboXXXI Congreso Nacional 30 de Junio al
Julio de 2015 Hotel Hesperia World Trade Center Valen...
Antimicrobial-resistant (AMR) infections claim hundreds of thousands of
lives around the globe annually. This problem is exacerbated by a steady increase in global
antimicrobial use and abuse in the clinic and agriculture, and a dearth of novel antimicrobials
making it to market. If these scenarios continue unchecked, AMR will cumulatively cost the global
economy at least 100 trillion dollars by 2050.
This three-day conference will focus on
the latest work understanding and combatting AMR, incorporating clinical perspectives on AMR
diagnostics and management, translational academic perspectives on design of drug regimens and
combinations that suppress AMR, pharma perspectives on recent successes and failures in novel
antimicrobial development and clinical trials, and basic science perspectives on the ecology and
transmission of evolving AMR determinants. While these stakeholders are similarly motivated to
identify and develop therapies to treat the exceptional, unmet medical need of worsening AMR, their
spheres rarely overlap at scientific conferences, leading to scientific communication barriers
between subject matter experts. This conference attempts to address this challenge by engaging
diverse global perspectives on these topics, bringing together speakers and attendees from research
academia, industrial drug development, and healthcare practice and policy. In summary, key goals are
Present and discuss the most current and cutting-edge results
regarding understanding and combatting antimicrobial resistance, including presentation of the
newest technologies, experimental approaches, and policy initiatives, as well as discussions of how
to speed their translation and clinical implementation;
current controversies that may slow progress in the field, and consider future directions, including
identification of the most pressing unanswered questions, the areas needing more focus, and those
that would benefit from new approaches and methodologies;
the gap between scientists from the academic research arena, pharma/industrial drug development, and
healthcare practice and policy.
Hear the following confirmed speakers
(additional speakers will be added, including short talks chosen from
Institute for Clinical Pharmacodynamics, USA Gavin Barlow, Hull and East
Yorkshire Hospitals, NHS Trust and University of York, UK Ilana L. Brito,
Cornell University, USA Carey-Ann D. Burnham, Washington University School of
Medicine, USA Karen Bush, Indiana University, USA Lynn
Connolly, Achaogen, USA Gautam Dantas, Washington University School of
Medicine, USA Thomas F. Durand-Reville, Entasis Therapeutics,
USA Danica Galonic Fujimori, University of California, San Francisco,
USA Lorraine D. Hernandez, Merck Research Laboratories, USA Kathryn
E. Holt, University of Melbourne, Australia Scott Hultgren, Washington
University School of Medicine, USA Ramanan Laxminarayan*, Center for Disease
Dynamics, Economics and Policy, India Jean Patel, Centers for Disease Control
and Prevention, USA Folkert Reck, Novartis Institutes for BioMedical Research,
USA Aileen Rubio, Spero Therapeutics, USA Paolo Ruggerone,
Università degli studi di Cagliari, Italy Gerry D. Wright, McMaster University,
Canada Pamela Yeh, University of California, Los Angeles, USA Helen
I. Zgurskaya, University of Oklahoma, USA
Scientific Organizers: Gautam
Dantas, Washington University School of Medicine Jennifer A. Leeds,
Novartis Institutes for BioMedical Research
Surveillance and Treatment of Resistant Bacterial Infections in Clinical Practice ? Workshop 1:
Novel Therapeutic Strategies ? Fate and Lessons Learned from Recent Drug Development Programs
Focused on Resistant Pathogens or Narrow-Spectrum Agents ? Alternative Approaches to Tackling
Resistant Infections ? Multidrug Evolutionary Strategies to Invert Resistance Selection ?
Ecology and Evolution of AMR Transmission Dynamics Across Habitats ? Workshop 2: Novel Strategies
for AMR Discovery, Diagnostics and Modeling ? Tackling AMR ? Challenges in Drug
Discounted abstract submission and discounted registration
save 50 USD and 200 USD, respectively, on later fees.
a poster is an excellent way to gain feedback on your work. Abstracts can be submitted through the
discounted registration deadline for poster presentation, but those submitted by the abstract
deadline will also be considered for short talk selection.
note that the first advertised meeting date is the date of arrival and registration, and the last
date that of the last organized sessions.
Symposia on Molecular and Cellular Biology is a 501(c)(3) nonprofit organization headquartered in
Colorado, USA that is directed and supported by the scientific community. 160 US Highway
6, Suite 200 | PO Box 1630 | Silverthorne, CO 80498 | USA 1-970-262-1230 | 1-800-253-0685 (in US &
The 2017-2018 Keystone Symposia conference season is about to begin, and I want to bring to your attention the following conferences, that according to our records, you may find of interest. Each conference name below is linked to the meeting webpage where you can find more details regarding the program and speakers, plus the discounted registration, abstract and scholarship deadlines.
The 2018 conferences in our Immunology series are:
Whether or not you can personally attend an upcoming Keystone Symposia conference, please spread the word about our conference season among your network of colleagues, and especially students and postdocs as the participation of early-career investigators is vital, and we offer scholarships to help defray their costs.
I welcome any email regarding our conferences or feedback on other Keystone Symposia-related topics. I am very proud of the Keystone Symposia staff and advisors and the outstanding programs we convene each year. We are always open to new ideas and suggestions.
I hope you will find time in the next year to attend one of the exciting symposia and that I might meet you face-to-face at a 2018 conference!
Sexual y Reproductiva Transdermal
Efficacy EditorialINTRODUCCION A CURSO AMEOLey Organica Violencia UNFPAManejo de AbortoCuidados de...
y la Vacuna de VPH
supplement -FIGO Declaración de FIGO sobre la Seguridad de la Vacunación del VPH, Agosto 2,
HPV vaccine ?could prevent 90% of ce...